Measurable residual disease predicts relapse, survival in AML
In acute myeloid leukaemia (AML) patients in their second complete morphological remission, measurable residual disease, in vivo T cell depletion, and the time from diagnosis to haematopoietic cell transplant all seem to correlate with relapse and leukaemia-free survival, a recent study has found.
